In a study of Lynch syndrome carriers, 83% of advanced adenomas and 58% of adenomas were mismatch repair-deficient, and the presence of Nous-209 mutations correlated strongly with microsatellite instability status, suggesting potential for preventive immunotherapy. (Cancer Prevention Research)
Nous-209 Immunotherapy Targets Appear Early in Lynch Syndrome Precancers
The CRC Digest